NUS Links:
Summary
The combination of chemotherapy (or targeted therapy) with immunotherapy is emerging rapidly as a promising strategy in the first line treatment against several tumor types. This study led by Dr Raghav Sundar provides the basis to further optimise treatment options for first-line metastatic GEAC patients using combination of Immunotherapy and chemotherapy.
Link to article: https://bit.ly/35WzvHy
This research, led by N2CR members Prof Goh Boon Cher and Prof Shazib Pervaiz with Dr Jayshree Hirpara as the …
Detecting cancer-driving mutations is crucial for understanding cancer and developing treatments. Existing prediction tools vary in accuracy. N2CR member A/Prof …
Led by N2CR member A/Prof Polly Chen, this research highlights the crucial role of ‘death associated protein 3’ (DAP3) in …